Ascentage Pharma Group International in 1 story
The narratives 6855.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
6855.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Ascentage has generated globally competitive hematology assets and secured a major Takeda option agreement for the China-developed leukemia therapy olverembatinib.
Bear side
0 storiesNo bear-side stories for 6855.HK yet.